[Phosphogliv: mechanism of therapeutic action and clinical efficacy].

The review summarizes the results of long term study (from design to clinical trial) of a new hepatoprotective drug Phosphogliv. Some theoretical ground for its creation has been considered with special emphasis on its ingredient properties: soy bean phosphatidylcholine and glycyrrhizinic acid from licorice roots. Experimental and clinical data concerning polyene phosphatidylcholine repairing action on cell membranes as well as antiviral and immunomodulating effects of glycyrrhizinic acid are presented. Their selected combination in Phosphogliv provided its high efficiency in rat hepatitis models. After standard toxicology tests it was allowed to carry out the clinical trials of this preparation in the treatment of liver diseases patients--mainly with acute and chronic viral hepatitis B, C, A and mixed hepatitis B + C (total 203 patients). The inclusion of Phosphogliv into therapy coarse accelerated disappearance of intoxication symptoms and decrease of serum aminotransferase and other hepatic markers. The effect was more pronounced for intravenous drug form.